[Skip to Navigation]
July 3, 2002

Hormone Replacement Therapy for Prevention: More Evidence, More Pessimism

Author Affiliations

Author Affiliation: Research and Evaluation, Kaiser Permanente Southern California, Pasadena.

JAMA. 2002;288(1):99-101. doi:10.1001/jama.288.1.99

Most physicians and researchers were surprised by the results of the Heart and Estrogen/progestin Replacement Study (HERS).1 This randomized trial assessed the efficacy of hormone replacement for secondary prevention of coronary heart disease (CHD)—that is, the ability of hormone replacement therapy (HRT) to prevent CHD events in women with established coronary disease. After an average of 4.1 years of follow-up, there was no overall difference in CHD end points between women randomized to receive placebo or HRT given as a continuous combined regimen of 0.625 mg/d of estrogen plus 2.5 mg of medroxyprogesterone acetate.